18 employees
Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
2021
$27M
from 3 investors over 3 rounds
Ariceum Therapeutics raised $27M on June 8, 2022
Investors: Pureos Bioventures, HealthCap and EQT Life Sciences